2m 2m 2m 2m 2m 2m 2m
Ascendis Pharma Br (ASND)
NASDAQ
$238.26+$10.25 (+4.50%)
Price as of Jun 23, 2026 6:21 PM EDT- $15.0BMarket Cap
- 29.71%1-Year Change
- BiotechnologyIndustry
Ascendis Pharma Br (ASND)
$238.26+$10.25 (+4.50%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 720.1M +98.03% | 363.6M +36.34% | 266.7M +421.20% | 51.2M +557.93% | |
Cost of Revenue | 94.9M +114.46% | 44.3M -0.31% | 44.4M +265.78% | 12.1M +244.51% | |
Gross Profit | 625.2M +95.76% | 319.4M +43.66% | 222.3M +469.52% | 39.0M +817.44% | |
Sales and Marketing Expense | 457.9M +57.27% | 291.1M +10.11% | 264.4M +19.52% | 221.2M +38.11% | |
Research and Development Expense | -303.6M -1.10% | -307.0M -25.75% | -413.5M +8.91% | -379.6M +28.31% | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 457.9M +57.27% | 291.1M +10.11% | 264.4M +19.52% | 221.2M +38.11% | |
Operating Profit | -136.3M -51.12% | -278.8M -38.81% | -455.5M -18.92% | -561.8M +24.35% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -80.6M +23.12% | -65.5M +48.65% | -44.1M +43.62% | -30.7M +684.51% | |
Interest Income and Expense and Net | -80.6M +23.12% | -65.5M +48.65% | -44.1M +43.62% | -30.7M +684.51% | |
Total Nonoperating Income and Expense | 80.6M +23.12% | 65.5M +48.65% | 44.1M +43.62% | 30.7M +684.51% | |
Income before Taxes | -228.0M -39.69% | -378.1M -21.47% | -481.4M -17.45% | -583.2M +52.04% | |
Income Taxes | 15.4M +217.63% | 4.8M -33.68% | 7.3M +35.82% | 5.4M +1,565.12% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -228.0M -39.69% | -378.1M -21.47% | -481.4M -17.45% | -583.2M +52.04% | |
Net Income from Continuing Operations Applicable to Common | -228.0M -39.69% | -378.1M -21.47% | -481.4M -17.45% | -583.2M +52.04% | |
Basic EPS and Net Income | -3.76 -42.42% | -6.53 -23.63% | -8.55 N/A | N/A N/A | |
Diluted EPS and Net Income | -3.76 -42.42% | -6.53 -23.63% | -8.55 N/A | N/A N/A | |
Basic Weighted Average Shares | 60.6M +4.69% | 57.9M +2.85% | 56.3M +0.38% | 56.1M +2.37% | |
Diluted Weighted Average Shares | 60.6M +4.69% | 57.9M +2.85% | 56.3M +0.38% | 56.1M +2.37% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 616.0M +10.10% | 559.5M +42.68% | 392.2M -11.83% | 444.8M -0.34% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 616.0M +10.10% | 559.5M +42.68% | 392.2M -11.83% | 444.8M -0.34% | |
Total Current Assets | 1.1B +4.54% | 1.1B +50.96% | 702.7M -23.90% | 923.5M +14.59% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 146.5M +48.39% | 98.7M -10.77% | 110.6M -14.30% | 129.1M +2.42% | |
Total Long-Term Assets | 193.6M +63.18% | 118.6M -3.44% | 122.9M -26.10% | 166.3M -40.41% | |
Total Assets | 1.3B +10.43% | 1.2B +42.87% | 825.6M -24.24% | 1.1B +0.44% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 429.4M -6.29% | 458.2M +3,981.66% | 11.2M -55.84% | 25.4M N/A | |
Total Current Liabilities | 1.1B +17.79% | 907.9M +360.04% | 197.3M +15.22% | 171.3M +70.66% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 396.0M +4.95% | 377.3M -51.24% | 773.9M +18.14% | 655.1M +549.08% | |
Total Liabilities | 1.5B +14.02% | 1.3B +32.32% | 971.3M +17.53% | 826.4M +310.56% | |
Retained Earnings | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Stockholders Equity | -162.8M +54.03% | -105.7M -27.45% | -145.7M -155.32% | 263.3M -70.20% | |
Total Shares Outstanding | 597,096 -29.41% | 845,887 N/A | N/A N/A | N/A N/A | |
Cash Flow | |||||
Cash from Operating Activities | 53.9M +117.60% | -306.2M -34.48% | -467.4M -5.72% | -495.7M +18.69% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -8.5M -223.40% | 6.9M -97.60% | 286.5M +364.06% | 61.7M +155.83% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 36.3M -91.82% | 443.9M +230.57% | 134.3M -66.15% | 396.8M +12.92% | |
Financials Ratio | |||||
Gross Margin | 86.82% -1.15% | 87.83% +5.37% | 83.36% +9.27% | 76.28% +39.44% | |
Operating Margin | -18.92% -75.32% | -76.66% -55.12% | -170.79% -84.44% | -1,097.85% -81.10% | |
Return on Assets | -18.37% -51.28% | -37.71% -24.98% | -50.27% -6.27% | -53.64% +44.35% | |
Return on Equity | 169.84% -43.53% | 300.78% +136.75% | -818.43% +704.82% | -101.69% +128.31% | |
Revenue Growth | 98.03% +169.77% | 36.34% -91.37% | 421.20% -24.51% | 557.93% +4,602.18% | |
Current Ratio | 1.04 -11.25% | 1.17 -67.19% | 3.56 -33.96% | 5.39 -32.86% | |
Cash Ratio | 0.58 -6.52% | 0.62 -68.99% | 1.99 -23.48% | 2.60 -41.60% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow